In this regard, specific delivery of aromatase-inhibitors exclusively to target cancer cells using antibody conjugated biodegradable nanoparticles provides a promising approach for increasing drug efficacy and reducing therapeutic side effects. This evidence concerns the gene CYP19A1 and cancer.